Trikafta 100-50-75 MG/150 MG UU 84S

The Defense Logistics Agency awarded a $19,332.22 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Trikafta 100-50-75 mg/150 mg tablets (84-count unit). The award, issued on January 5, 2026, with an ultimate completion date of January 6, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical supply support to Department of Defense military healthcare facilities worldwide. The parent IDC, designated SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, and authorizes the issuance of delivery orders for branded and generic prescription drugs, biologics, and medical consumables.

DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its small business status and demonstrated performance across numerous delivery orders spanning therapeutic categories from oncology treatments to routine medications and specialty pharmaceuticals. The company's registered status in the System for Award Management since July 18, 2001, combined with consistent contract performance supporting the Defense Logistics Agency's Medical Supply Chain division, positions it to fulfill the specialized pharmaceutical requirements of the military medical system. As the sole awardee on this delivery order with no identified subcontractors, DMS Pharmaceutical Group maintains direct accountability for timely delivery of Trikafta, a critical cystic fibrosis treatment, to support Department of Defense healthcare operations.